![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1440358
½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ : ¼¼°è ½ÃÀå Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Global Nerve Monitoring System - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
¼¼°èÀÇ ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2024³â 14¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2029³â±îÁö 18¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£(2024-2029³â) µ¿¾È 5.52%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ÆÒµ¥¹Í ÃâÇöÀº ¼¼°è °æÁ¦¿Í °Ç° °ü¸® ½Ã½ºÅÛ¿¡ ¼Õ»óÀ» ÀÔÇû½À´Ï´Ù. 2021³â 2¿ù¿¡ ¹ßÇ¥µÈ ¿¬±¸ ¡¸COVID-19·ÎºÎÅÍ È¸º¹ÇÑ È¯ÀÚ¿¡ ÀÖ¾î¼ÀÇ ½Å°æ Àüµµ ¿¬±¸ ¹× ±ÙÀüµµ °Ë»çÀÇ °á°ú-Áõ·Ê º¸°í¡¹¿¡ ÀÇÇϸé, ½Å°æ Àüµµ ¿¬±¸ ¹× ±ÙÀüµµ °Ë»çÀÇ °á°ú´Â ½Å°æ°ú ±ÙÀ°¿¡ ´ëÇÑ COVID-19ÀÇ Á÷Á¢ÀûÀÎ ÀÛ¿ëÀ» ½Ã»çÇϰí ÀÖ½À´Ï´Ù. SARSCOV-2 Å»¼ö¼º ´Ù¹ß¼º ´º·ÎÆÄƼ¿Í ¹Ì¿ÀÆÄƼÀÇ ¿ä¼Ò´Â ½ÅÇü COVID-19Áõ °ü¸®¿¡¼ °í·ÁÇØ¾ß ÇÒ »õ·Î¿î º´¸®ÇÐÀû ½Çü°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ COVID-19¸¦ °ü¸®Çϱâ À§ÇÑ ½Å°æ ¸ð´ÏÅ͸µ ±â¼úÀÇ µµÀÔÀ¸·Î ÀÌ·¯ÇÑ ÀåÄ¡ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ±×·¯³ª Á¦Á¶ °øÀåÀÇ ÀϽÃÀûÀÎ ºÀ¼â, ¼÷·Ã ³ëµ¿ÀÚ ºÎÁ·, Á¦Á¶ °øÀå ³» COVID-19Áõ Áõ°¡·Î ÀÎÇØ Áß´ÜÀÌ ¹ß»ýÇÏ¿© ½ÃÀå ¼ºÀåÀÌ ¹æÇØµÇ°í ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. µû¶ó¼ À§ÀÇ ¿äÀÎÀº COVID-19°¡ Á¶»ç ´ë»ó ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù.
Á¶»çµÈ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ½Å°æ ¸ð´ÏÅ͸µ ÀýÂ÷¿Í °ü·ÃµÈ ÀÓ»óÀû ÀÌÁ¡°ú ¿Ü»ó »ç·Ê¿¡¼ ½Å°æ ¸ð´ÏÅ͸µÀÇ »ç¿ë Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ, Á¦Ç° Ãâ½Ã, ½ÂÀÎ, ¿¬±¸°³¹ß Ȱµ¿ÀÇ ¼ºÀå, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Àü·«Àû ³ë·ÂÀÌ ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2020³â 7¿ù ¿µ±¹ ½ÉÀåÀç´ÜÀÌ ¹ßÇ¥ÇÑ ¿¬±¸ °á°ú¿¡ µû¸£¸é ¿µ±¹¿¡¼´Â ¾à 750¸¸¸íÀÌ ½ÉÀ庴À» ¾Î°í ÀÖÀ¸¸ç ¸Å³â 17¸¸¸í °¡±îÀÌ »ç¸ÁÇϰí ÀÖ½À´Ï´Ù. ¿µ±¹¿¡¼´Â ½ÉÇ÷°ü Àå¾Ö(CVD)·Î ÀÎÇØ ÇÏ·ç Æò±Õ 460¸í ¶Ç´Â 3ºÐ¿¡ ÇÑ ¸íÀÇ »ç¸ÁÀÌ ¹ß»ýÇÕ´Ï´Ù. °Ô´Ù°¡ ¼¼°èº¸°Ç±â±¸¿¡ ÀÇÇÑ 2021³â 2¿ùÀÇ ÃÖ½ÅÁ¤º¸¿¡ µû¸£¸é ¼¼°è ¾à 17¾ï 1,000¸¸¸íÀÌ ±Ù°ñ°Ý°è ÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀ¸·Î ÀÎÇÑ ºÎ´ãÀÌ Å©¹Ç·Î ¼ö¼úÀÇ ¹ß»ý·üµµ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ½Å°æ±â´ÉÀÇ °¨½Ã°¡ ÇÊ¿äÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ¼ö¿ä°¡ ¼¼°èÀûÀ¸·Î ³ô¾ÆÁö°í ½ÃÀåÀÌ °ßÀεǰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, Á¶»ç ´ë»ó ½ÃÀå¿¡¼ÀÇ Á¦Ç° Ãâ½Ã´Â ±â¼úÀûÀ¸·Î °í±Þ Á¦Ç°À» µµÀÔÇÏ¿© ¼öÀͼºÀÌ ³ôÀº ½ÃÀåÀÇ ¼ºÀåÀ¸·Î À̾îÁú °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 6¿ù ¼è¾à¼º ¸¸¼º ÅëÁõÀ¸·Î °íÅë¹Þ´Â ȯÀÚÀÇ ÁøÅë °³¼±¿¡ ÁßÁ¡À» µÐ ÀÇ·á±â±â ȸ»çÀÎ Neuralace Medical, Inc.Àº ºñħ½ÀÀûÀ¸·Î ¸»ÃʽŰæÀ» ÀÚ±ØÇÏ¿© ¸¸¼ºÀûÀÎ ÅëÁõÀ» ¿ÏÈÇÏ´Â Ãà»è ¿ä¹ýÀÇ FDA 510(k) Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù. °Ô´Ù°¡ 2022³â 3¿ù¿¡´Â Çѱ¹°úÇбâ¼ú¿ø(KAIST)ÀÇ ¿¬±¸ÀÚµéÀÌ ÆÈÀÇ ¿òÁ÷ÀÓ Áß¿¡ ³úÀÇ ½Å°æ ½ÅÈ£¸¦ ÇØµ¶ÇÏ´Â µ¶½É ½Ã½ºÅÛÀ» °³¹ßÇß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ³úÆÄ °Ë»ç(EEG) ¹× ÇÇÁú Àü±â °Ë»ç(ECoG) ±â¼úÀ» »ç¿ëÇÕ´Ï´Ù.
°Ô´Ù°¡ ÆÄÆ®³Ê½Ê, È®´ë, Àμö µîÀÇ Àü·«Àû ³ë·Âµµ ½ÃÀåÀÇ È¹±âÀûÀÎ ¼ºÀåÀ¸·Î À̾îÁý´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ù Assure Holdings Corp.´Â Conductiv°ú ¼ö¼ú Áß ½Å°æ ¸ð´ÏÅ͸µ ¼ºñ½º¿¡ ´ëÇÑ ±×·ì ±¸¸Å °è¾à('GPO')À» ü°áÇß½À´Ï´Ù. ÀÌ °è¾àÀ» ÅëÇØ 500°³ÀÇ º´¿ø°ú ¼ö¼ú¼¾ÅÍ, 50°³ ÀÌ»óÀÇ ÀÇ·á ½Ã½ºÅÛÀ» Æ÷ÇÔÇÑ Conductiv ȸ¿øÀº AssureÀÇ ÇÕµ¿ À§¿øÈ¸ ÀÎÁõ ¼ö¼ú Áß ½Å°æ ¸ð´ÏÅ͸µ ¼ºñ½ºÀÇ Æ¯º° °¡°Ý°ú »çÀü Çù»ó Á¶°ÇÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
µû¶ó¼ ¾Õ¼ ¾ð±ÞÇÑ ¿äÀÎÀ¸·Î Á¶»ç ´ë»ó ½ÃÀåÀº Á¶»ç ±â°£ µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ÀÇ·á Àü¹®°¡µé »çÀÌ¿¡¼ ½Å°æ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ÀǽÄÀÌ Á¦ÇѵǾî Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ ¹æÇعÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³ú½Å°æ ¼ö¼úÀº ³ú, ô¼ö, ôÃß ¹× ½ÅüÀÇ ¸ðµç ºÎºÐÀÇ ¸»ÃÊ ½Å°æ¿¡ »óÇØ, Áúº´ ¶Ç´Â Àå¾Ö°¡ ÀÖ´Â »ç¶÷µéÀ» Ä¡·áÇÕ´Ï´Ù. ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀåÀÇ ½Å°æ ¿Ü°ú ºÎ¹®Àº ½Å°æ ¼Õ»óÀ» ÀÏÀ¸Å³ ¼öÀÖ´Â ½Å°æ Áúȯ ¹× Àå¾Ö ºÎ´ãÀÌ ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ°í ¼ö¼ú ¼ö·® Áõ°¡·Î À̾îÁö°í Àֱ⠶§¹®¿¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ¸·Î ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ÀýÂ÷´Â ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ Çʿ伺À» »ý¼ºÇÏ°í ¿¹Ãø ±â°£ µ¿¾È ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù.
¼¼°è ³ëÀÎÃþ¿¡¼ ¾ËÃ÷ÇÏÀ̸Ӻ´°ú ÆÄŲ½¼º´, ÇåÆÃÅϺ´, ¿îµ¿´º·± Áúȯ µî ½Å°æÅðÇ༺ ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼, ÀÌ´Â ÁøÇ༺ ½Å°æ±â´ÉºÎÀü°ú µ¶¼ºÀ¸·Î À̾îÁ® È¿°úÀûÀÎ ½Å°æÁ¶Àý ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. µû¶ó¼ ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½Å°æ Áúȯ ºÎ´ãÀÌ Áõ°¡ÇÏ°í ¿¹Ãø ±â°£ µ¿¾È ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ Á¶»ç ´ë»ó ½ÃÀå¿¡¼ Á¦Ç° ½ÂÀÎÀ» ÅëÇØ Á¦Ç° Á¦°øÀÌ È®´ëµÇ°í ±â¼úÀûÀ¸·Î °í±Þ Á¦Ç°ÀÌ µµÀÔµÇ¾î ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, iMediSync´Â 2021³â 1¿ù¿¡ AI Ŭ¶ó¿ìµå Ç÷§ÆûÀÎ iSyncBrain¿¡¼ ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸ÅÀÇ Á¶±â °ËÃâÀ» À§ÇÑ EEG µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½ÃÀÛÇß½À´Ï´Ù. AI ºÐ¼®°ú ³ú ¸ÅÇÎ ±â¼úÀ» ÅëÇØ ÀÌ È¸»ç´Â ÇâÈÄ Ãâ½ÃµÉ »õ·Î¿î Çìµå¼Â iSyncWave¸¦ »ç¿ëÇÏ¿© ´º·± Ȱµ¿À» °ÈÇÏ´Â °³ÀÎÈµÈ NIR-LED ½Å°æ Á¶Àýµµ Á¦°øÇÕ´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»ç ´ë»ó ºÎ¹®ÀÌ ½ÃÀåÀÇ ´ëÆøÀûÀÎ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹ÌÀÇ ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀº ½Å°æ ¸ð´ÏÅ͸µ ÀýÂ÷¿Í °ü·ÃµÈ ÀÓ»ó ÇýÅðú ¿Ü»ó »ç·Ê¿¡¼ ½Å°æ ¸ð´ÏÅ͸µ »ç¿ë Áõ°¡ÀÔ´Ï´Ù. °Ô´Ù°¡ Á¦Ç° Ãâ½Ã Áõ°¡, ¿Ü°ú ¼ö¼ú Áõ°¡, ¿¬±¸°³¹ß Ȱµ¿ Áõ°¡, ÇÕº´, Àμö ¹× ÆÄÆ®³Ê½Ê µî ±âŸ Àü·«Àû ³ë·Âµµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì ³» ¹Ì±¹Àº Á¶»ç ±â°£ µ¿¾È Á¶»ç ´ë»ó ½ÃÀåÀÇ Å« Á¡À¯À²À» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 9¿ù¿¡ ¾÷µ¥ÀÌÆ®µÈ Áúº´ °ü¸® ¿¹¹æ ¼¾ÅÍ(CDC)ÀÇ '½ÉÀ庴 »ç½Ç'À̶ó´Â Á¦¸ñÀÇ ±â»ç¿¡ µû¸£¸é, ½ÉÀ庴Àº ¹Ì±¹ÀÇ ÁÖ¿ä »ç¸Á ¿øÀÎÀÌ µÇ¾ú½À´Ï´Ù. ÀÌ Á¤º¸¿øÀº ¸Å³â ¾à 80¸¸ 5,000¸íÀÇ ¹Ì±¹ÀÎÀÌ ½ÉÀå ¹ßÀÛÀ» ÀÏÀ¸Å°°í ÀÖ´Ù°í º¸°íÇϰí ÀÖ½À´Ï´Ù. ½ÉÀ庴¿¡ ÀÇÇÑ ºÎ´ãÀÌ Å©¹Ç·Î ¸¹Àº ½ÉÀå ¿Ü°ú ¼ö¼úÀÌ ÁøÇàµÇ¾î ½Å°æ ¼Õ»óÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ ¼ö¿ä´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°Ô´Ù°¡ Á¦Ç° °³¹ß°ú °ü·Ã ±â¼ú Çõ½ÅÀº ´õ ¸¹Àº ÀÌÁ¡À» Á¦°øÇÏ°í ±âÁ¸ÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í ¼öÀͼºÀÌ ³ôÀº ½ÃÀåÀÇ ¼ºÀåÀ¸·Î À̾îÁú °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 5¿ù, ´º·Î»çÀÎÀº V4 4ä³Î ¹× 8ä³Î ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛ¿¡ ´ëÇØ ¹Ì±¹ ½ÄǰÀǾ౹ÀÇ Çã°¡¸¦ ¹Þ¾Ò½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¹Ì±¹¿¡¼ ³ú ½Å°æ, µÎ°³°ñÀÇ ±âÃÊ ¼ö¼ú ¹× ô¼ö ½Å°æ±Ù µî¿¡ ´ëÇÑ ½Å°æ ½Äº° ¹× º¸Á¸À» À§ÇØ È¯ÀÚ¿¡°Ô »ç¿ëµË´Ï´Ù.
°Ô´Ù°¡, Á¶»ç ´ë»ó ½ÃÀå¿¡¼ ¿¬±¸°³¹ß Ȱµ¿ÀÇ È°¼ºÈ´Â ±âÁ¸ Ä¡·á¹ýÀÇ È¿´ÉÀ» Æò°¡Çϰí ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀ» °ÈÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ½ÃÀåÀ» °ßÀÎÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù¿¡ ¹ßÇ¥µÈ '¾ãÀº ÆÄ¸±·» C Çʸ§¿¡ À×Å©Á¬ ÀμâµÈ À¯¿¬ÇÑ Àü±â ÇÇÁú °Ë»ç(ECoG) ¸¶ÀÌÅ©·Î Àü±Ø ¾î·¹ÀÌ'¶ó´Â Á¦¸ñÀÇ ¿¬±¸¿¡¼ °úÇÐÀÚµéÀº ¾ãÀº ÆÄ¸±·» ±â¹ÝÀÇ À¯¿¬ÇÑ 22ä³Î ECoG ¹Ì¼¼Àü±Ø ¾î·¹À̸¦ °³¹ßÇÏ¿© ½ÃÇè°ü³» ¹× »ýü³» ¼º´É°ú ±× È¿°ú¸¦ ÀÔÁõÇÏ¿´½À´Ï´Ù. ±×µéÀº ¿¬±¸¿¡¼ ±àÁ¤ÀûÀÎ °á°ú¸¦ º¸°íÇÏ°í ÆÄ¸±·» ±â¹ÝÀÇ À¯¿¬ÇÑ ¹Ì¼¼ Àü±Ø ÆÐÅϰú ±â¼úµÈ ½Å±Ô Á¦Á¶ ±â¼úÀÌ ½Å°æ°úÇÐ ¹× ºê·¹ÀÎ ¸Ó½Å ÀÎÅÍÆäÀ̽º¿¡ Àß Àû¿ëµÉ ¼ö ÀÖÀ½À» º¸¿©ÁÖ¾ú½À´Ï´Ù. µû¶ó¼ ÀÌ·¯ÇÑ ¿¬±¸ÀÇ ±àÁ¤ÀûÀÎ °á°ú´Â ±¹°¡ÀÇ ½Å°æ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÇ µµÀÔÀ» ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.
µû¶ó¼ À§ÀÇ ¿äÀεé·Î ÀÎÇØ Á¶»çµÈ ½ÃÀåÀº ºÏ¹Ì ½ÃÀåÀÇ À¯¸®ÇÑ ¼ºÀåÀ¸·Î À̾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Á¶»ç ´ë»ó ½ÃÀåÀº Àû´çÇÑ °æÀï·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ ÇÕº´, Àμö, ÆÄÆ®³Ê½Ê µî Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºê´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Medtronic, NuVasive Inc., Natus Medical, Nippon Kotsu, Checkpoint Surgical Inc. µîÀÔ´Ï´Ù.
The Global Nerve Monitoring System Market size is estimated at USD 1.41 billion in 2024, and is expected to reach USD 1.85 billion by 2029, growing at a CAGR of 5.52% during the forecast period (2024-2029).
The emergence of the COVID-19 pandemic harmed the world economy and the healthcare system. According to the study 'Nerve conduction study and electromyography findings in patients recovering from Covid-19 - Case report,' published in February 2021, nerve conduction studies and electromyography findings suggest a direct action of COVID-19 on nerves and muscles. SARSCOV-2 demyelinating polyneuropathy and elements of myopathy could be new pathological entities to be considered in COVID-19 management. Thus, implementing nerve monitoring techniques to manage COVID-19 has increased the demand for these devices, thus impacting the market growth. However, the market growth was hampered due to the temporary lockdown in the manufacturing plants, shortage of skilled labor, and increasing cases of COVID-19 inside the manufacturing plants, which has led to outages, thus, impacting the market. Hence, the above factors indicate that COVID-19 significantly impacted the studied market.
The factors propelling the studied market growth are clinical benefits associated with nerve monitoring procedures and the rising use of nerve monitoring in trauma cases. Additionally, product launches, approvals, growing research and development activities, and strategic initiatives by key market players are expected to contribute to significant market growth.
According to a study published by the British Heart Foundation in July 2020, there were approximately 7.5 million people with heart disease in the United Kingdom and nearly 170,000 deaths each year. An average of 460 fatalities each day or one death every three minutes happen in the United Kingdom due to cardiovascular disorders (CVDs). Furthermore, to a February 2021 update by the World Health Organization, approximately 1.71 billion people have musculoskeletal conditions worldwide. Due to the high burden of chronic diseases, the incidences of surgeries are also expected to increase, which may need the monitoring of nerve functioning. This factor boosts the demand for nerve monitoring systems globally, thus, driving the market.
Additionally, product launches in the studied market are expected to introduce technologically advanced products, leading to lucrative market growth. For instance, in June 2021, NeuraLace Medical, Inc., a medical device company focused on improving pain relief among patients suffering from debilitating chronic pain, received FDA 510(k) clearance for Axon Therapy to non-invasively stimulate peripheral nerves and provide chronic nerve pain relief. Additionally, in March 2022, Researchers from the Korea Advanced Institute of Science and Technology (KAIST) developed a mind-reading system for decoding neural signals from the brain during arm movement. This system uses electroencephalography (EEG) and electrocorticography (ECoG) techniques.
Moreover, strategic initiatives such as partnerships, expansions, and acquisitions will also lead to significant market growth. For instance, in April 2022, Assure Holdings Corp. entered into a group purchasing agreement ('GPO') for intraoperative neuromonitoring services with Conductiv. The agreement allows Conductiv members, which includes 500 hospitals and surgery centers and more than 50 health systems, to take advantage of special pricing and pre-negotiated terms for Assure's Joint Commission accredited intraoperative neuromonitoring services.
Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, limited awareness about nerve monitoring among healthcare professionals is expected to hinder the market growth during the forecast period.
Neurosurgery involves treating people with injuries, diseases, or disorders of the brain, spinal cord and spinal column, and peripheral nerves within all body parts. The neurosurgery segment of the nerve monitoring system market is expected to have a positive impact on the growth of the segment, owing to the rising burden of neurological diseases and disorders around the world which may result in nerve damage, leading to the increasing volume of surgical procedures creates the need of nerve monitoring system, thus boosting the growth in the segment over the forecast period.
There is a growing burden of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, Huntington's disease, and motor neuron diseases, among others, in the older population across the world. Thus, this leads to progressive neural dysfunction and toxicities, increasing the demand for effective nerve modulation device, thereby driving growth in the studied market. Thus, with the increasing geriatric population, the burden of neurological diseases may increase and boost the segment's growth during the forecast period. For instance, according to the 2022 Alzheimer's Association report, an estimated 6.5 million Americans aged 65 and older will live with Alzheimer's dementia in 2022. Due to the increasing burden of Alzheimer's Disease, brain surgeries are expected to increase, creating the need for a nerve monitoring system over time.
Additionally, product approvals in the studied market will expand the product offerings and introduce technologically advanced products, contributing to the market growth. For instance, in January 2021, iMediSync launched EEG digital biomarker for early detection of Alzheimer's dementia on their AI cloud platform, iSyncBrain. With AI analytics and brain mapping techniques, the company also serves personalized NIR-LED neuromodulation using their upcoming novel headset, iSyncWave, to enhance neuronal activity.
Thus, due to the abovementioned factors, the studied segment is expected to contribute to the significant growth of the market.
The primary driving factors for the growth of the North American nerve monitoring system market are clinical benefits associated with nerve monitoring procedures and the rising use of nerve monitoring in trauma cases. In addition, rising product launches, a rise in surgical procedures, increasing research and development activities, and other strategic initiatives such as mergers and acquisitions and partnerships are also expected to drive the market growth.
The United States within North America is expected to hold a significant share of the studied market during the study period. For instance, according to the Centers for Disease Control and Prevention (CDC) 's Article titled 'Heart Disease Facts,' updated in September 2020, Heart disease is the leading cause of death in the United States. The same source also reports that about 805,000 Americans have a heart attack every year. Due to the high burden of cardiac disease, many cardiology surgical procedures are performed, which may result in nerve damage. Therefore, the demand for nerve monitoring systems is expected to boost the market growth.
Additionally, product development and associated technological innovation will offer more advantages and overcome the existing challenges, leading to lucrative market growth. For instance, in May 2021, Neurosign gained United States Food and Drug Administration clearance for the V4 4-channel and 8-channel nerve monitoring system, which is being used on patients for nerve identification and preservation in the United States for cranial nerves, skull base surgeries, and spinal nerve roots.
Moreover, rising research and development activities in the studied market will help evaluate the efficacies of existing treatment and boost the pipeline of drugs, thus driving the market. For instance, in a study titled "An Inkjet-Printed Flexible Electrocorticography (ECoG) Microelectrode Array on a Thin Parylene-C Film," published in February 2022, scientists developed a thin Parylene-based flexible 22-channel ECoG microelectrode array and demonstrated its performances in vitro and in vivo. They reported positive results from their study, indicating that Parylene-based flexible microelectrode patterns and the novel fabrication techniques described have successful applications in neuroscience and brain-machine interfaces. Thus, positive results from these studies will boost the country's adoption of the nerve monitoring systems, thus driving the market growth.
Therefore, due to the abovementioned factors, the studied market is expected to lead to lucrative growth of the market in North America.
The studied market is moderately competitive. The strategic initiatives such as mergers and acquisitions and partnerships adopted by key market players will boost the market growth. The market's major players are Medtronic, NuVasive Inc., Natus Medical, Nihon Koden, Checkpoint Surgical Inc., and others.